Holger Rosenbrock

1.6k total citations
62 papers, 1.2k citations indexed

About

Holger Rosenbrock is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Holger Rosenbrock has authored 62 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 25 papers in Cellular and Molecular Neuroscience and 15 papers in Pharmacology. Recurrent topics in Holger Rosenbrock's work include Neuroscience and Neuropharmacology Research (21 papers), Phosphodiesterase function and regulation (14 papers) and Cholinesterase and Neurodegenerative Diseases (13 papers). Holger Rosenbrock is often cited by papers focused on Neuroscience and Neuropharmacology Research (21 papers), Phosphodiesterase function and regulation (14 papers) and Cholinesterase and Neurodegenerative Diseases (13 papers). Holger Rosenbrock collaborates with scholars based in Germany, United States and Canada. Holger Rosenbrock's co-authors include Katja S. Kroker, Cornelia Dorner‐Ciossek, Eliza Koroś, Georg Rast, Franco Borsini, Niklas Schuelert, Glen Wunderlich, Frank Sams‐Dodd, Michael Desch and Jana Podhorná and has published in prestigious journals such as Journal of Neuroscience, Biochemistry and The Journal of Comparative Neurology.

In The Last Decade

Holger Rosenbrock

62 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Holger Rosenbrock Germany	23	525	512	264	206	184	62	1.2k
Laura M. Gault United States	16	349 0.7×	431 0.8×	174 0.7×	124 0.6×	180 1.0×	24	1.0k
Kazuki Nagayasu Japan	22	493 0.9×	587 1.1×	154 0.6×	223 1.1×	192 1.0×	86	1.5k
Fraser Murray United Kingdom	22	423 0.8×	568 1.1×	206 0.8×	103 0.5×	298 1.6×	25	1.3k
Valérie Compan France	21	539 1.0×	853 1.7×	197 0.7×	210 1.0×	180 1.0×	39	1.4k
Ouissame Mnie‐Filali France	18	413 0.8×	747 1.5×	241 0.9×	209 1.0×	86 0.5×	31	1.1k
Estelle Barbier United States	23	614 1.2×	799 1.6×	228 0.9×	284 1.4×	210 1.1×	35	1.6k
Radmila Manev United States	19	389 0.7×	420 0.8×	174 0.7×	139 0.7×	130 0.7×	36	1.2k
Christophe Melon France	24	543 1.0×	1.3k 2.5×	196 0.7×	234 1.1×	153 0.8×	46	1.8k
Ayhan Şık Netherlands	10	585 1.1×	445 0.9×	341 1.3×	238 1.2×	143 0.8×	10	1.1k
Antonio Luchicchi Netherlands	22	545 1.0×	888 1.7×	503 1.9×	332 1.6×	227 1.2×	35	1.6k

Countries citing papers authored by Holger Rosenbrock

Since Specialization

Citations

This map shows the geographic impact of Holger Rosenbrock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Rosenbrock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Rosenbrock more than expected).

Fields of papers citing papers by Holger Rosenbrock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Rosenbrock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Rosenbrock. The network helps show where Holger Rosenbrock may publish in the future.

Co-authorship network of co-authors of Holger Rosenbrock

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Rosenbrock. A scholar is included among the top collaborators of Holger Rosenbrock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Rosenbrock. Holger Rosenbrock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenbrock, Holger, et al.. (2024). Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies. British Journal of Clinical Pharmacology. 90(10). 2517–2528. 2 indexed citations

Rosenbrock, Holger, Michael Desch, & Glen Wunderlich. (2023). Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 273(7). 1557–1566. 49 indexed citations

Just, Stefan, Angelo Ceci, Boris Ferger, et al.. (2022). P376. Preclinical Pharmacological Characterization of the Selective NR2b Negative Allosteric Modulator BI 1569912 With Potential to Treat MDD. Biological Psychiatry. 91(9). S239–S239. 1 indexed citations

Jaeger, Stefan, Rolf Sprengel, Bastian Hengerer, et al.. (2022). Increasing the Excitatory Drive Rescues Excitatory/Inhibitory Imbalance and Mismatch Negativity Deficit Caused by Parvalbumin Specific GluA1 Deletion. Neuroscience. 496. 190–204. 5 indexed citations

Mattei, Daniele, Cornelia Dorner‐Ciossek, Michael Sand, et al.. (2021). Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders. Neuropsychopharmacology. 46(8). 1526–1534. 10 indexed citations

Desch, Michael, Glen Wunderlich, Karl‐Heinz Liesenfeld, et al.. (2021). Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics. 47(1). 91–103. 6 indexed citations

Mueller, Flavia S., Roberto Arban, Cornelia Dorner‐Ciossek, et al.. (2020). Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders. Brain Behavior and Immunity. 88. 461–470. 28 indexed citations

Toader, Oana, Moritz von Heimendahl, Niklas Schuelert, Wiebke Nissen, & Holger Rosenbrock. (2019). Suppression of Parvalbumin Interneuron Activity in the Prefrontal Cortex Recapitulates Features of Impaired Excitatory/Inhibitory Balance and Sensory Processing in Schizophrenia. Schizophrenia Bulletin. 46(4). 981–989. 25 indexed citations

Rosenbrock, Holger, Riccardo Giovannini, Gerhard Schänzle, et al.. (2019). The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents. Journal of Pharmacology and Experimental Therapeutics. 371(3). 633–641. 27 indexed citations

10.

Moschetti, Viktoria, Maria Kim, Michael Sand, et al.. (2018). The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers. European Neuropsychopharmacology. 28(5). 643–655. 10 indexed citations

11.

Rosenbrock, Holger, Michael Desch, Oliver Kleiner, et al.. (2018). Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. Clinical and Translational Science. 11(6). 616–623. 33 indexed citations

12.

Schuelert, Niklas, et al.. (2017). 669. GPR52 Agonists Represent a Novel Approach to Treat Cognitive Deficits Associated with Schizophrenia. Biological Psychiatry. 81(10). S271–S271. 4 indexed citations

13.

Lausser, Ludwig, Florian Schmid, Cathrin Schnack, et al.. (2017). Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. Alzheimer s Research & Therapy. 9(1). 17–17. 37 indexed citations

14.

Heimendahl, Moritz von, et al.. (2016). PM537. GPR52 agonists show pro-cognitive properties. The International Journal of Neuropsychopharmacology. 19(Suppl_1). 95–95. 1 indexed citations

15.

Lamla, Thorsten, et al.. (2016). Overexpression of Protein Kinase Mζ in the Hippocampus Enhances Long-Term Potentiation and Long-Term Contextual But Not Cued Fear Memory in Rats. Journal of Neuroscience. 36(15). 4313–4324. 22 indexed citations

16.

Kroker, Katja S., et al.. (2014). PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiology of Aging. 35(9). 2072–2078. 52 indexed citations

17.

Kroker, Katja S., Georg Rast, & Holger Rosenbrock. (2011). Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP. Neuropharmacology. 61(4). 707–714. 14 indexed citations

18.

Koroś, Eliza, et al.. (2006). The Selective mGlu5 Receptor Antagonist MTEP, Similar to NMDA Receptor Antagonists, Induces Social Isolation in Rats. Neuropsychopharmacology. 32(3). 562–576. 70 indexed citations

19.

Rosenbrock, Holger, et al.. (2005). Effect of chronic intermittent restraint stress on hippocampal expression of marker proteins for synaptic plasticity and progenitor cell proliferation in rats. Brain Research. 1040(1-2). 55–63. 114 indexed citations

20.

Singeç, Ilyas, Rolf Knoth, Margarethe Ditter, et al.. (2002). Synaptic vesicle protein synaptoporin is differently expressed by subpopulations of mouse hippocampal neurons. The Journal of Comparative Neurology. 452(2). 139–153. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact